Royalty Ranges in Biotech Deals
Executive Summary
Often the most contentious-and, therefore, closely guarded-aspects of biotech/pharma alliances is the royalties a biotech licenser will receive upon commercialization of the technology or product it has licensed to a partner. We've charted the outside ranges of royalties in biotech deals since 1991 by clinical phase to get a handle on where they tend to fall.